MRI/US fusion prostate biopsy: Our initial experience

Vito Lacetera 1, Bernardo Cervelli 1, Antonio Cicetti 1, Giuliana Gabrielloni 1, Michele Montesi 1, Roberto Morcellini 1, Gianni Parri 1, Emilio Recanatini 1, Gianluca Giglioli 2, Andrea Benedetto Galosi 2, Valerio Beatrici 1

1 Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy; 2 Clinica Urologica, Università Politecnica delle Marche, Azienda Ospedaliera Ospedali Runiti, Ancona, Italy.

INTRODUCTION

Transrectal ultrasound-guided random biopsy of the prostate (TRUSB) is still the recommended standard tool for the diagnosis of prostate cancer (PCA) (1). This approach is a blindly sampled of the prostate without focus on any specific lesion; there are several limitations in this approach, including failure to detect clinically significant PCA (due to undersampling); imprecise tumor risk stratification (undergrading) and detection of small, low risk clinically insignificant cancers (overdiagnosis) (2). Undersampling can occur in up to 30% of cases with clinically significant tumors being missed on initial biopsy; undergrading is estimated at 46% of cases considered at low risk of progression candidates for active surveillance, based on preoperative systematic biopsy, but with an upgraded Gleason score of 7 or greater at final histopathology (3).

These diagnostic limitations can lead to repeat biopsies (with related side effects and costs), delayed detection of significant PCA and over treatment. Efforts to overcome sampling error include performing multiple repeat biopsies and increasing the core number; this resulted in the overdetection of indolent cancers; morbidity attributed to unnecessary biopsies and an increase in cost.

Several studies have shown that when serial biopsies are indicated, most cancers that are detected are clinically insignificant and the rate of indolent cancer detection increases (4, 5). Recently, a 3-D stereotactic mapping of the prostate has been proposed in order to have a threedimensional histological mapping of the gland: this technique can be made by a templated-guided transperineal biopsy that requires anaesthesia (spinal or sedation) and hospitalization, or by a software based transrectal biopsy that records all tracks of the needle on a 3-D map with only a local anaesthesia. This technique should allow not overlapping needle’s tracks with a better 3-D volumetric distribution of the biopsies into the prostatic gland and than a better determination of the extent and location of cancer before definitive therapy (6). Advances in imaging have led to the application of magnetic resonance imaging (MRI) for the detection of PCA (7-12) with subsequent development of software-based co-registration allowing for the integration of MRI with real-time TRUS during prostate biopsy. A number of fusion-guided methods and platforms are now commercially available.

Submitted 15 November 2016; Accepted 15 December 2016

KEY WORDS: MRI/US fusion biopsy; Prostate cancer; Prostate biopsy.
with common elements in image and analysis and planning (13-15). We present our initial experience with one of these platforms after the first consecutive 59 patients.

**MATERIALS AND METHODS**

Between May 2016 and October 2016, we prospectively evaluated the first consecutive 59 patients who underwent to TRUS biopsy using Trinity Koelis® (Koelis, Grenoble, France) MRI/US Fusion machine. We divided the patients into 2 groups: patients with a previous negative mapping who underwent to a MRI/US fusion re-biopsy (Group A); and biopsy-naïve patients who underwent to a first stereotactic 3-D mapping of the prostate (Group B). MRI images were obtained using a 1.5 T scanner with a pelvic phased array coil, each suspicious area was further characterized according to the ESUR PI-RADS v.1 global score (12), MRI were done in different hospital without a central review. Two different urologists made all the biopsies. All biopsy core specimens were examined by 2 urogenital pathologists and graded according to the 2005 International Society of Urological Pathology Modified Gleason Grading System (16). Characteristics of the patients (summarized in Table 1) were in Group A: n° of patients = 22, mean age 64 years (CI 48-73), mean PSA = 7.7 ng/ml (CI 4.2-9.9), mean prostate volume = 55 ml (CI 45-82), Digital Rectal Examination (DRE) positive ratio = 2/22, number of lesions detected by MRI 1.4 (17 PIRADS 3, 4 PIRADS 4, 1 PIRADS 5), mean cores from each MRI target lesion = 3 (CI 2-5), mean total cores = 15 (CI 12-19). In Group B: n° of patients = 37, mean age 66 years (CI 49-77), mean PSA = 4.7 (3.2-7.9); mean prostate volume = 45 ml (33-67), DRE positive ratio = 5/37, mean total cores = 14 (CI 10-16). We standardized our MRI/US fusion biopsy technique using Koelis Trinity in 5 steps:

**First step:** MRI T2 and/or DWI images are loaded into the Trinity, we manually border the prostate signing the apex, the base the mid gland and additional landmarks of the prostate obtaining a 3-D MRI volume; than we target the suspected areas described in the MRI report in a semiautomatic process. This step is usually done the day before procedure.

**Second step:** a 3D TRUS volume is obtained by a real-time TRUS examination in 3 planes (transversal, 60 degree longitudinal turning the probe on the right and on left) by an end fire probe with a rotating 360 degree head. We border the prostate volume in a similar way to MRI process.

**Third step:** automatic elastic fusion of the MRI and ultrasound volumes is done by the machine’s software pressing a button. We check the correct fusion of the volumes.

**Fourth step:** virtual simulation of bioptical tracking with a visual feedback on the fused target volume is done.

**Fifth step:** if the virtual simulation of the track is inside the target lesion, we press the button of the needle and a real biopsy is done followed by 3D-TRUS acquisition of the real track with the needle still in the gland. A mean of 2 cores were obtained from each MRI-target area. Then at least a 12-core random biopsy were performed in all patients. In case of stereotactic first round biopsy in biopsy naïve patient (Group B) step 1 and 3 are avoided, we recorded all real track in a 3-D TRUS map.

**RESULTS**

Our results are summarized below and displayed in Table 2. Group A (22 patients): 10/22 positive for PCA (overall detection rate of 45.5%). 6 PCA were detected by target biopsy and 4 cancer by random biopsy. Significant prostate cancer (defined as the presence of Gleason pattern 4) was detected in 4/10 patients (significant PCA detection rate of 40%), all significant PCA were detected in MRI target biopsy (1/17 PIRADS 3, 2/4 PIRADS 4, 1/1 PIRADS 5). All PCA detected by random biopsy had Gleason score 3 + 3 = 6.

Group B (37 biopsy naïve patients): 14/37 positive for PCA (overall detection rate of 37.8%). Significant prostate cancer was detected in 5/14 patients (significant PCA detection rate of 35.7%).

The mean time of the procedure was 42 min (C.I. 22-55) in the initial 10 patients and 17 min in the following 10 patients (C.I. 19-35) in Group A, 27 min (C.I. 19-45) in the initial 10 patients and 17 min in the following 10 patients (C.I. 10-25) in Group B.

No significant side effects were recorded in either group (such as fever, urinary retention, urosepsis, and hospitalization).

**Table 1.**

Characteristics of the patients.

**Group A:** patients with a previous negative mapping who underwent to a MRI/US fusion re-biopsy.

**Group B:** biopsy-naïve patients who underwent to a first stereotactic 3-D mapping of the prostate.

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>22</td>
<td>37</td>
</tr>
<tr>
<td>Mean age</td>
<td>64</td>
<td>66</td>
</tr>
<tr>
<td>Mean PSA</td>
<td>7,7</td>
<td>4,7</td>
</tr>
<tr>
<td>DRE positive</td>
<td>2/22</td>
<td>5/37</td>
</tr>
<tr>
<td>Mean Prostate Volume</td>
<td>55</td>
<td>46</td>
</tr>
<tr>
<td>Total cores</td>
<td>15</td>
<td>14</td>
</tr>
<tr>
<td>Mean core from each target</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>PIRADS 3</td>
<td>17/22</td>
<td></td>
</tr>
<tr>
<td>PIRADS 4</td>
<td>4/22</td>
<td></td>
</tr>
<tr>
<td>PIRADS 5</td>
<td>1/22</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.**

Results.

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall PCA detection rate</td>
<td>10/22 (45.5%)</td>
<td>14/37 (37.8%)</td>
</tr>
<tr>
<td>Significant PCA detection rate</td>
<td>4/10 (40%)</td>
<td>5/14 (35.7%)</td>
</tr>
<tr>
<td>PCA in target lesion</td>
<td>6/10</td>
<td></td>
</tr>
<tr>
<td>PCA in random biopsy core</td>
<td>4/10</td>
<td></td>
</tr>
<tr>
<td>Significant PCA detected in target lesion</td>
<td>4/6</td>
<td></td>
</tr>
<tr>
<td>PIRADS 3</td>
<td>1/6</td>
<td></td>
</tr>
<tr>
<td>PIRADS 4</td>
<td>2/6</td>
<td></td>
</tr>
<tr>
<td>PIRADS 5</td>
<td>1/6</td>
<td></td>
</tr>
<tr>
<td>Significant PCA in random biopsy core</td>
<td>0/4</td>
<td></td>
</tr>
</tbody>
</table>
DISCUSSION

We considered many commercial platforms of co-registered MRI/US fusion biopsy devices commercially available. These devices vary by method of co-registration (mechanical, electromagnetic or real-time) and use a different hardware platform to align the biopsy with the co-registered image. We chose Trinity Koelis because we considered this option to be the best compromise between accuracy, reproducibility and feasibility in our daily practice. A recent systematic review shows that MRI-TRUS image fusion targeted biopsies detect more clinically significant cancers compared with standard biopsy techniques: the median detection rate of any cancer was 43.4% and 50.5% in the standard biopsy strategy versus MRI-TRUS image fusion biopsy; the median detection of clinically significant disease was 23.6% (range: 4.8-52%) for standard biopsy and 33.3% (range: 13.2-50%) for MRI-TRUS image fusion targeted biopsy. However, patient populations differ quite a bit between the different studies regarding the amount of patients with a previous negative biopsy or patients that were biopsy naive (17). Our overall detection rate was 45.5% and 37.8% in MRI-US fusion biopsy (patients with previous negative biopsy and persistent suspicion of PCA) and in stereotactic biopsy (biopsy naive patients); clinical significant PCA detection rate was respectively 40% and 35.7%. These results are similar to those reported in the current literature and promising for the future. The main limitations of our study were the small number of patients, difference in expertise of the radiologists, our learning curve of at least the first 10 cases.

Until now our main problems using this technique are the following: it is not easy to border the target lesion without radiologist’s help if it is visible only in DWI sequence; because this is a freehand procedure (operator dependent technique) without a probe stepper, even a little movement of the probe in the passage from virtual track simulation to real biopsy could miss the target lesion (especially if the diameter is < 1 cm).

CONCLUSIONS

MRI/US fusion biopsy in patients with a previous negative mapping but persistent suspicion of PCA represents a useful tool to address many of the limitations of contemporary systematic re-biopsy (reduce false-negatives, improve risk classification, contribute to the reduction of repeat biopsies and over-detection). Among men with no previous biopsy its role is poorly defined, but we believe that at least a stereotactic first biopical mapping (recording all biopical tracks in a 3-D map) can not only increase cancer detection rate but, if a re-biopsy will be necessary, a MRI-US fusion biopsy can be done using the previous recorded 3-D map, avoiding the same tracks of first mapping and improving the results of this technique. We believe that among men with suspicion of PCA, stereotactic first mapping and MRI/US fusion re-biopsy potentially improves risk stratification and reduces understaging, undergrading and the need for repeat biopsies. The optimal method for MR targeted biopsy has not yet been established; further comparative studies with standard of practice and evaluation of cost-effectiveness are warranted.
REFERENCES

Correspondence
Vito Lacetera, MD, Urologist
vito.lacetera@gmail.com
Bernardo Cervelli, MD, Urologist
Bernardo.Cervelli@ospedalimarchenord.it
Antonio Cicetti, MD, Urologist
antonio.cicetti@ospedalimarchenord.it
Gianluca Giglioni, MD
Gianluca.Giglioni@ospedalimarchenord.it - piullu88@gmail.com
Michele Montesi, MD, Urologist
michele.montesi@ospedalimarchenord.it
Roberto Morcellini, MD, Urologist
roberto.morcellini@ospedalimarchenord.it
Gianni Parri, MD, Urologist
Gianni.parri@ospedalimarchenord.it
Emilio Recanatini, MD, Urologist
Emilio.recanatini@ospedalimarchenord.it
Valerio Beatrici, MD, Urologist
Valerio.Beatrici@ospedalimarchenord.it
Azienda Ospedaliera Ospedali Riuniti Marche Nord
Piazzale Cinelli 4, 61121. Pesaro, Italy
Andrea Benedetto Galosi, MD, Associate Professor of Urology
galosiah@yahoo.it
Clinica Urologica, Università Politecnica delle Marche,
Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy